Bioven, the late-stage biopharmaceutical company focused on cancer, is pleased to announce that it has secured an option to exclusive US marketing rights to EGF-PTI, a novel immunotherapy which the Company is currently progressing in an international, pivotal Phase III trial in non-small cell lung cancer (NSCLC).
Bioven earlier this year filed an updated Investigational New Drug application with the US Food & Drug Administration so that US study centres can be included in its current Phase III trial. ...show more
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.